Molecular tumour board helps in advanced cancer cases

With accelerating development of personalised cancer treatments matched to a patient's DNA sequencing, proponents say frontline physicians increasingly need help to maneuver through the complex genomic landscape to find the most effective, individualised therapy. In a recent paper, researchers at the University of California, San Diego School of Medicine and Moores Cancer Center detail their experience evaluating 34 patients between December 2012 and June 2013 using a molecular tumour board – a new type of advisory group comprised of multidisciplinary experts, including those in the fields of tumour genetics, basic science and bioinformatics. Read more here.